David Kirn, M.D., is the Chief Executive Officer of 4D Molecular Therapeutics Inc., a leading clinical-stage biotherapeutics company focused on developing genetic medicines for large-market diseases. Dr. Kirn brings extensive experience in the biotechnology industry, having founded and led several successful companies. He holds an M.D. from Stanford University School of Medicine and completed his residency in internal medicine at Massachusetts General Hospital. His postdoctoral fellowship in molecular virology at MIT further solidified his expertise in the field. Before joining 4D Molecular Therapeutics, Dr. Kirn founded Jennerex Biotherapeutics, where he served as President and CEO. Under his leadership, Jennerex developed a novel oncolytic virus therapy for cancer treatment, which led to a successful acquisition by SillaJen in 2014. Dr. Kirn's career also includes a significant tenure at Genentech, where he contributed to the development of multiple cancer therapies, including Avastin and Herceptin. His strategic vision and scientific acumen have been instrumental in advancing innovative treatments from concept to clinical application. As CEO of 4D Molecular Therapeutics, Dr. Kirn oversees the company's mission to develop and commercialize targeted genetic medicines. His leadership has been pivotal in advancing the company's product pipeline, which includes therapies for ophthalmology, cardiology, and pulmonology. Dr. Kirn's commitment to leveraging cutting-edge technology and his deep understanding of the genetic medicine landscape position 4D Molecular Therapeutics at the forefront of the industry. Under his guidance, the company continues to make significant strides in bringing transformative treatments to patients worldwide.